MARKET

LAB

LAB

STANDARD BIOTOOLS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.600
+0.650
+33.33%
Pre Market: 2.450 -0.15 -5.77% 06:35 05/24 EDT
OPEN
1.910
PREV CLOSE
1.950
HIGH
2.620
LOW
1.870
VOLUME
1.92K
TURNOVER
--
52 WEEK HIGH
7.51
52 WEEK LOW
1.850
MARKET CAP
200.86M
P/E (TTM)
-1.7083
1D
5D
1M
3M
1Y
5Y
58 Biggest Movers From Yesterday
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.
Benzinga · 1h ago
BRIEF-Standard Biotools Inc Files For Stock Shelf Of Up To 75.2 Million Shares
reuters.com · 6d ago
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Standard BioTools Non-GAAP EPS of -$0.25 misses by $0.07, revenue of $26.5M beats by $0.85M
Standard BioTools press release (NASDAQ:LAB): Q1 Non-GAAP EPS of -$0.25 misses by $0.07. Revenue of $26.5M (-14.5% Y/Y) beats by $0.85M.
Seekingalpha · 05/05 21:22
Standard BioTools Q1 EPS $(0.25) Down From $(0.15) YoY, Sales $26.50M Beat $25.60M Estimate
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.25) per share. This is a 66.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of
Benzinga · 05/05 21:10
-- Earnings Flash (LAB) STANDARD BIOTOOLS Posts Q1 Revenue $26.5M, vs. Street Est of $25.7M
MT Newswires · 05/05 16:45
4 Stocks Under $3 Insiders Are Aggressively Buying
Gold futures traded slightly higher on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested i...
Benzinga · 05/03 14:07
Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging
Capacity to Process 100-Plus Samples per Week, with 1.6x Lower Limit of DetectionSOUTH SAN FRANCISCO, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in...
GlobeNewswire · 04/11 12:30
More
No Data
Learn about the latest financial forecast of LAB. Analyze the recent business situations of STANDARD BIOTOOLS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LAB stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.
High6.00
Average6.00
Low6.00
Current 2.600
EPS
Actual
Estimate
-0.79-0.59-0.40-0.20
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 168
Institutional Holdings: 54.47M
% Owned: 70.51%
Shares Outstanding: 77.25M
TypeInstitutionsShares
Increased
26
3.50M
New
10
1.36M
Decreased
41
3.24M
Sold Out
23
7.19M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.07%
Healthcare Equipment & Supplies
+0.73%
Key Executives
Non-Executive Chairman/Independent Director
Carlos Paya
President/Chief Executive Officer/Director
Michael Egholm
Chief Financial Officer
Vikram Jog
Chief Operating Officer/Senior Vice President/Director of Investor Relations
Alex Kim
Chief Human Resource Officer
Angela Peters
Senior Vice President/General Counsel/Secretary
Nicholas Khadder
Senior Vice President
Bradley Kreger
Senior Vice President
Emi Zychlinsky
Other
Colin Mccracken
Director
Eli Casdin
Director
Martin Madaus
Director
Franklin Witney
Independent Director
Gerhard Burbach
Independent Director
Laura Clague
Independent Director
Bill Colston
No Data
No Data
About LAB
Fluidigm Corporation creates, manufactures, and markets a range of products and services, including instruments, consumables, reagents, and software that are used by researchers and clinical labs. The Company operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. It markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

Webull offers kinds of Fluidigm Corporation stock information, including NASDAQ:LAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LAB stock methods without spending real money on the virtual paper trading platform.